5-Methoxy-1'-methylspiro[indoline-3,4'-piperidin]-2-one

Catalog No.: 
ACGWZY216
CAS No.: 
742067-27-2
Molecular Formula: 
C14H18N2O2
Molecular Weight: 
246.31
5-Methoxy-1'-methylspiro[indoline-3,4'-piperidin]-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$185.00InquiryInquiry
1g95%$561.00InquiryInquiry
5g95%$2749.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Methoxy-1'-methylspiro[indoline-3,4'-piperidin]-2-one
IUPAC Name5-methoxy-1'-methylspiro[indoline-3,4'-piperidin]-2-one
Molecular FormulaC14H18N2O2
Molecular Weight246.31
SMILESO=C1NC2=C(C=C(OC)C=C2)C13CCN(C)CC3
InChI KeyNUOATCLREIKYDA-UHFFFAOYSA-N
Synonym1''-METHYL-5-METHOXYSPIRO[INDOLE-3,4''-PIPERIDINE]2(1H)ONE;1,2-Dihydro-2-oxo-1'-methylspiro[5-methoxy-3H-indole-3,4'-piperidine];5-Methoxy-1-methylspiro[indoline-3,4-piperidin]-2-one;Spiro[3H-indole-3,4'-piperidin]-2(1H)-one, 5-methoxy-1'-methyl-
CAS No.742067-27-2

Synthetic Route by SureRoute

1. ACGWZY216 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQVKH312 route compound structure diagram
    ACQVKH3121184-54-9In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGWZY216 route product structure diagram
    ACGWZY216742067-27-2
Inquiry

2. ACGWZY216 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGWZY216 route product structure diagram
    ACGWZY216742067-27-2
Inquiry

3. ACGWZY216 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGWZY216 route product structure diagram
    ACGWZY216742067-27-2
Inquiry

Comments (0)